Sino Biopharmaceutical Limited (SINOBIOPHARM) income statement

HKSE · Healthcare · Medical - Pharmaceuticals · 22,838 employees · CEO S. Y. Tse

Price: HK$4.86 +0.83%
Market cap: HK$86.5B
Enterprise value: CN¥75.5B
Last report: Q2 '26 filed 2026-06-30
Next report: 2027-04-01

Sino Biopharmaceutical Limited (SINOBIOPHARM) reported revenue of CN¥9.72B for Q2 '26 (+10.6% year on year), operating income of CN¥3.42B (35.2% of revenue) and net income of CN¥1.72B. Over the last four quarters revenue was CN¥33.7B.

Income statement

Income statement	Q1 '23	Q2 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26
Revenue	CN¥7.14B	CN¥7.14B	CN¥7.94B	CN¥7.94B	CN¥6.5B	CN¥6.5B	CN¥8.79B	CN¥8.79B	CN¥7.13B	CN¥7.13B	CN¥9.72B	CN¥9.72B
Cost of revenue	CN¥1.63B	CN¥1.63B	CN¥1.42B	CN¥1.42B	CN¥1.25B	CN¥1.25B	CN¥1.54B	CN¥1.54B	CN¥1.31B	CN¥1.31B	CN¥1.65B	CN¥1.65B
Gross profit	CN¥6.01B	CN¥6.01B	CN¥6.51B	CN¥6.51B	CN¥5.25B	CN¥5.25B	CN¥7.25B	CN¥7.25B	CN¥5.82B	CN¥5.82B	CN¥8.07B	CN¥8.07B
Research & development	CN¥1.18B	CN¥1.18B	CN¥1.29B	CN¥1.29B	CN¥1.26B	CN¥1.26B	CN¥1.59B	CN¥1.59B	CN¥1.42B	CN¥1.42B	CN¥1.54B	CN¥1.54B
Sales & marketing	CN¥2.69B	CN¥2.69B	CN¥2.9B	CN¥2.9B	CN¥2.14B	CN¥2.14B	CN¥3.22B	CN¥3.22B	CN¥2.27B	CN¥2.27B	CN¥2.63B	CN¥2.63B
General & administrative	CN¥531M	CN¥531M	CN¥526M	CN¥526M	CN¥515M	CN¥515M	CN¥547M	CN¥547M	CN¥525M	CN¥525M	CN¥485M	CN¥485M
Other operating expenses	-CN¥125M	-CN¥125M	CN¥0	CN¥0	CN¥146M	CN¥146M	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0	CN¥0
Operating expenses	CN¥4.28B	CN¥4.28B	CN¥4.71B	CN¥4.71B	CN¥4.06B	CN¥4.06B	CN¥5.37B	CN¥5.37B	CN¥4.22B	CN¥4.22B	CN¥4.65B	CN¥4.65B
Operating income	CN¥1.56B	CN¥1.56B	CN¥1.8B	CN¥1.8B	CN¥1.34B	CN¥1.34B	CN¥1.88B	CN¥1.88B	CN¥1.6B	CN¥1.6B	CN¥3.42B	CN¥3.42B
Interest income	CN¥3.08M	CN¥3.08M	CN¥0	CN¥0	CN¥449M	CN¥449M	CN¥928M	CN¥928M	CN¥0	CN¥0	CN¥0	CN¥0
Other non-operating income (gains on investments, FX ...)	CN¥46.9M	CN¥46.9M	CN¥66.8M	CN¥66.8M	CN¥489M	CN¥489M	CN¥177M	CN¥177M	CN¥154M	CN¥154M	CN¥113M	CN¥113M
Total non-operating income	-CN¥39.2M	-CN¥39.2M	CN¥5.34M	CN¥5.34M	-CN¥507M	-CN¥507M	CN¥1.1B	CN¥1.1B	-CN¥1.11B	-CN¥1.11B	CN¥251M	CN¥251M
Income before tax	CN¥1.53B	CN¥1.53B	CN¥1.81B	CN¥1.81B	CN¥832M	CN¥832M	CN¥2.98B	CN¥2.98B	CN¥488M	CN¥488M	CN¥3.67B	CN¥3.67B
Income tax	CN¥249M	CN¥249M	CN¥307M	CN¥307M	CN¥60.6M	CN¥60.6M	CN¥491M	CN¥491M	CN¥324M	CN¥324M	CN¥598M	CN¥598M
Net income	CN¥629M	CN¥629M	CN¥1.51B	CN¥1.51B	CN¥241M	CN¥241M	CN¥1.69B	CN¥1.69B	-CN¥523M	-CN¥523M	CN¥1.72B	CN¥1.72B
EPS (basic)	CN¥0.03	CN¥0.03	CN¥0.04	CN¥0.04	CN¥0.01	CN¥0.01	CN¥0.09	CN¥0.09	-CN¥0.03	-CN¥0.03	CN¥0.10	CN¥0.10
EPS (diluted)	CN¥0.03	CN¥0.03	CN¥0.04	CN¥0.04	CN¥0.01	CN¥0.01	CN¥0.09	CN¥0.09	-CN¥0.03	-CN¥0.03	CN¥0.10	CN¥0.10
Shares (basic, weighted)	18.6B	18.6B	18.5B	18.4B	17.2B	17.2B	18B	18B	18B	18B	18B	18B
Shares (diluted, weighted)	18.6B	18.6B	18.5B	18.4B	18.2B	18.2B	18B	18B	18B	18B	18B	18B
Depreciation & amortization	CN¥315M	CN¥315M	CN¥255M	CN¥255M	CN¥305M	CN¥305M	CN¥288M	CN¥288M	CN¥318M	CN¥318M	CN¥273M	CN¥273M
EBITDA	CN¥1.83B	CN¥1.83B	CN¥1.99B	CN¥1.99B	CN¥1.15B	CN¥1.15B	CN¥1.99B	CN¥1.99B	CN¥1.76B	CN¥1.76B	CN¥3.58B	CN¥3.58B

Income statement	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	CN¥13.5B	CN¥14.8B	CN¥20.9B	CN¥24.2B	CN¥23.6B	CN¥26.9B	CN¥26B	CN¥26.2B	CN¥28.9B	CN¥31.8B
Cost of revenue	CN¥2.95B	CN¥3.09B	CN¥4.2B	CN¥4.93B	CN¥5.18B	CN¥5.33B	CN¥4.49B	CN¥4.99B	CN¥5.34B	CN¥5.71B
Gross profit	CN¥10.7B	CN¥11.7B	CN¥16.7B	CN¥19.3B	CN¥18.5B	CN¥21.5B	CN¥21.5B	CN¥21.2B	CN¥23.5B	CN¥26.1B
Research & development	CN¥1.37B	CN¥1.6B	CN¥2.09B	CN¥2.4B	CN¥2.63B	CN¥3.75B	CN¥4.33B	CN¥4.47B	CN¥5.23B	CN¥6.04B
Sales & marketing	CN¥5.45B	CN¥5.92B	CN¥8.08B	CN¥9.32B	CN¥8.97B	CN¥10.5B	CN¥9.81B	CN¥9.19B	CN¥10.1B	CN¥11B
General & administrative	CN¥1.09B	CN¥987M	CN¥2.19B	CN¥2.59B	CN¥2.66B	CN¥2.19B	CN¥1.9B	CN¥1.87B	CN¥2.08B	CN¥2.14B
Other operating expenses	CN¥0	-CN¥33.9M	CN¥13.6M	-CN¥198M	CN¥17.9M	CN¥0	-CN¥88.7M	CN¥0	CN¥0	CN¥0
Operating expenses	CN¥7.87B	CN¥8.47B	CN¥12.4B	CN¥14.1B	CN¥14.3B	CN¥16.5B	CN¥16B	CN¥15.5B	CN¥17.4B	CN¥19.2B
Operating income	CN¥2.86B	CN¥3.22B	CN¥4.32B	CN¥5.2B	CN¥4.19B	CN¥5.16B	CN¥5.59B	CN¥5.67B	CN¥6.14B	CN¥6.95B
Interest income	CN¥38.9M	CN¥83.1M	CN¥163M	CN¥258M	CN¥194M	CN¥162M	CN¥196M	CN¥187M	CN¥500M	CN¥617M
Interest expense	CN¥76.6M	CN¥77.9M	CN¥153M	CN¥230M	CN¥323M	CN¥309M	CN¥429M	CN¥495M	CN¥295M	CN¥271M
Other non-operating income (gains on investments, FX ...)	CN¥0	-CN¥1.01B	-CN¥7.26B	-CN¥723M	CN¥93.3M	CN¥0	-CN¥165M	CN¥181M	CN¥0	CN¥662M
Total non-operating income	CN¥342M	CN¥971M	CN¥7.11B	CN¥493M	CN¥821M	CN¥13.5B	-CN¥371M	-CN¥260M	-CN¥858M	-CN¥10.2M
Income before tax	CN¥3.2B	CN¥4.2B	CN¥11.4B	CN¥5.69B	CN¥5.01B	CN¥18.6B	CN¥5.21B	CN¥5.41B	CN¥5.28B	CN¥6.94B
Income tax	CN¥475M	CN¥542M	CN¥696M	CN¥903M	CN¥672M	CN¥1.96B	CN¥697M	CN¥797M	CN¥493M	CN¥1.63B
Net income	CN¥1.64B	CN¥2.17B	CN¥9.05B	CN¥2.76B	CN¥2.77B	CN¥14.6B	CN¥2.54B	CN¥2.33B	CN¥3.5B	CN¥2.34B
EPS (basic)	CN¥0.10	CN¥0.13	CN¥0.49	CN¥0.15	CN¥0.15	CN¥0.78	CN¥0.11	CN¥0.10	CN¥0.10	CN¥0.13
EPS (diluted)	CN¥0.10	CN¥0.13	CN¥0.49	CN¥0.15	CN¥0.15	CN¥0.73	CN¥0.12	CN¥0.10	CN¥0.10	CN¥0.13
Shares (basic, weighted)	16.7B	16.7B	18.5B	18.8B	18.8B	18.8B	18.6B	18.5B	17.2B	18.1B
Shares (diluted, weighted)	16.7B	16.7B	18.5B	18.8B	18.8B	19.3B	19B	18.5B	18.3B	18.1B
Depreciation & amortization	CN¥317M	CN¥343M	CN¥1.18B	CN¥1.47B	CN¥1.65B	CN¥993M	CN¥1.05B	CN¥1.07B	CN¥1.32B	CN¥1.21B
EBITDA	CN¥3.39B	CN¥4.62B	CN¥5.6B	CN¥7.37B	CN¥5.75B	CN¥19.9B	CN¥6.69B	CN¥6.98B	CN¥6.49B	CN¥7.5B

Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in CNY.

Revenue, operating income and growth

quarterly

Margins

quarterly

Costs as % of revenue

quarterly

The other statements

Balance sheetCash, investments, assets, debt, liabilities and equityOpen Cash flowOperating cash flow, capex, free cash flow, buybacks and dividendsOpen

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings.

Data as of 2026-11-02 · Amounts in CNY as reported; price and market cap in HKD.